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ERK1/2Mitogen-activated protein kinase kinase 1 (MAP2K1/MEK1) as well as Yes-associated protein (YAP),
the downstream effector of Hippo signaling pathway, is linked to hepatocarcinogenesis. However,
little is known about whether and how MEK1 interacts with YAP. In this study, we ﬁnd that
MEK1-YAP interaction is critical for liver cancer cell proliferation and maintenance of transformed
phenotypes both in vitro and in vivo. Moreover, MEK1 and YAP proteins are closely correlated in
human liver cancer samples. Mechanistically, inhibition of MEK1 by both PD98059 and U0126 as
well as RNAi reduces beta-transducin repeat containing E3 ubiquitin protein ligase (BTRC), which
acts as a potential endogenous YAP protector.
Structured summary of protein interactions:
YAP physically interacts with MEK1 by anti tag coimmunoprecipitation (View interaction)
BTRC and MEK1 colocalize by ﬂuorescence microscopy (View interaction)
YAP physically interacts with MEK1 by anti bait coimmunoprecipitation (View interaction)
MEK1 physically interacts with BTRC by anti tag coimmunoprecipitation (View interaction)
BTRC physically interacts with MEK1 by anti bait coimmunoprecipitation (View interaction)
MEK1 and YAP colocalize by ﬂuorescence microscopy (View interaction)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction tion, expression of inﬂammation-related genes involved inLiver cancer is the ﬁfth most common cancer worldwide and the
third leading cause of cancer death [1]. The treatment options for
these hepatic malignancies are extremely limited mainly because
themechanismsof pathogenesis of these cancers are not completely
known. Recently, dysfunctional Hippo/YAP signaling pathway has
been linked to hepatocarcinogenesis [2,3]. Ectopic increased expres-
sion of YAP in the immortalized non-tumorigenic hepatocyte cell
line confers tumorigenic andmetastatic potentials [4]. YAP contrib-
utes to human hepatocellular carcinoma (HCC) cell dedifferentia-carcinogenesis, resistance toward doxorubicin, and in vivo HCC cell
growth through induction of connective tissue growth factor (CTGF)
[5]. By using cross-species analysis of expression data, the Notch li-
gand Jagged-1 (Jag-1) was identiﬁed as a downstream target of YAP
in HCC cells. Overexpression of YAP upregulates Jag-1, leading to
activation of Notch pathway and increased proliferation [6]. Having
an essential role in cellular growth, knockout of the YAP gene inmice
could lead to early embryonic lethality [7]. Althoughmuch is known
about its function, the cross-talk betweenYAPandotherpathways is
still poorly understood. Recently, we indentiﬁed a close relationship
between YAP and CREB, which forms a positive regulatory feedback
relying on the Mitogen-activated protein kinase 14 (MAPK14)/P38
[8]. However, overexpression of CREB only partly rescued inhibitory
effects induced by knockdown of YAP [8], leading us to explore po-
tential proteins contributing to YAP carcinogenic property in liver
cancer.
Other thanMAPK14/P38, MEK/ERK proteins belong tomitogenic
signaling cascade as well. ERK1/2 is activated by MEK1/2, which is
activated by phosphorylation through MEK kinases (or MEKK) [9].
3922 L. Li et al. / FEBS Letters 587 (2013) 3921–3927Studies have shown thatMEK/ERK signaling cascade is a key regula-
tory enzyme pathway for control points within the cell cycle [10],
and activation of MEK/ERK is sufﬁcient to transform several cell
types, including NIH3T3 cells [11], suggesting its potential role in
cancer. There are several lines of evidence suggest an association be-
tween the MEK/ERK signaling pathway and liver cancers [12], and
the two most common causes of HCC, hepatitis B and C, have viral
proteins that activate MEK/ERK signaling [13,14]. Recently, YAP is
reported involved in the hepatocarcinogenesis mediated by Hepati-
tis B virus X protein (HBx), providing evidence that YAP can be also
activated by hepatitis viral infection [15]. However, no studies have
speciﬁcally linked Hippo/YAP and MEK/ERK in the liver cancers.
In the present study, we highlight the role of the interaction be-
tween YAP and MEK1 in liver cancer tumorigenesis. We found
MEK1 promotes YAP protein expression through beta-transducin
repeat containing E3 ubiquitin protein ligase (BTRC). Our data also
showed that YAP and MEK1 were closely correlated in tumor
samples, suggesting the important role of their interaction in liver
cancer. Taken together, this work summarized a novel link between
two major oncoproteins and a potential mechanism for liver
tumorigenesis.Fig. 1. MEK and YAP has similar function. (A) Up-regulation of MEK1 in liver cancer
and corresponding adjacent normal tissues from 15 patients. (B) Validation of MEK
with either 15 lM U0126, 30 lM PD98059 or DMSO. (C) Blockage of MEK inhibits ER
15 lM U0126, 30 lM PD98059 (+) or DMSO (). (D) Inhibition of MEK or YAP reduc
indicated (15 lM U0126 or 30 lM PD98059) were seeded (1  105) and cultured f
assays. Bel-7402 and SMMC-7721 cells treated as indicated (15 lM U0126 or 30 lM
shown as relative number of colonies as a percentage to that in control (treated
measured for 24 days after subcutaneous injection of 5  106 Bel-7402 cells under
Student t test.2. Materials and methods
2.1. Cell culture and vectors
HepG2, Bel-7402, SMMC-7721, and HEK-293T cells were cul-
tured in DMEM. Cells were treated by PD98059 (15–50 lM, Cell
Signaling Technology (CST), Boston, MA, USA) or U0126 (1–
20 lM, CST) 24 h before harvest. ShRNAs were cloned into pLKO.1
lentiviral vectors using primers as follows: MEK1-sh#1-Forward:
CCGGAACTCTGGATCAAGTCCTGAACTCGAGTTCAGGACTTGATCCA-
GAGTTTTTTTG and Reward: AATTCAAAAAAACTCTGGATCAAGTC C
TGAACTCGAGTTCAGGACTTGATCCAGAGTT; MEK1-sh#2-Forward:
CCGGAAGGACTCATTACTCTGTGCACTCGAGTGCACAGAGTAATGAGT
CCTTTTTTTG and Reward: AATTCAAAAAAAGGACTCATTACTCTG
TGCACTCGAGTGCACAGAGTAATGAGTCCTT. Expression vectors for
YAP and BTRC as well as shRNA against BTRC or YAP were obtained
from our previously study [8]. ERK1 and MST1 expression vectors
as well as pUAS-LUC/TEAD-Gal4 system were constructed as de-
scribed previously [16–18]. MEK1-HA was ampliﬁed by PCR from
corresponding cDNA purchased from Origene (Beijing, China) and
subcloned into pcDNA3.1(+) using following primers: Forward:tissues. Western blotting of proteins as indicated in a mix pool of liver cancer
inhibitors. Western blotting of phorspho-/total-MEK1 in Bel-7402 cells treated
K1/2. Western blotting of phorspho-/total ERK1/2 in Bel-7402 cells treated with
es cell proliferation. Bel-7402 and SMMC-7721 cells under different treatment as
or another 5 days before analyzed using the MTT assay. (E) Colony formation
PD98059) were plated in soft agar and further cultured for 4 weeks. The data is
with DMSO or control-shRNA). (F) Xenograft analysis. Tumor volumes were
different treatment as indicated. n = 5 per group. ⁄P < 0.05 and ⁄⁄P < 0.01 using
L. Li et al. / FEBS Letters 587 (2013) 3921–3927 3923GATTGGATCCATGCCCAAGAAGAAGCCGACGCCCATC and Reward:
CCGACTCGAGTTAAGCGTAGTCTGGGACGTCGTATGGGTAGACGCCA
GCAGCATGGGTTGGTG.2.2. Immunohistochemistry (IHC), immuneﬂuorescence (IF), and
Western bloting (WB)
For IHC, human liver cancer tissue microarray (TMA) slides
were purchased from U.S. Biomax (Rockville, MD, USA). Slides were
incubated in primary antibodies against MEK1 (CST, #2352) and
YAP65 (Epitomics, Burlingame, CA, USA #2060).
For IF, cells were incubated in primary antibodies against YAP
(CST, # 4912), MEK1 (CST, #2352) or BTRC (CST, # 4394).
For WB, primary antibodies used were: Flag (Sigma,
#F3165 or CST, # 2368), HA (CST, #3724 or #2367), YAP
(Epitomics, #2060), BTRC (CST, #4394), MEK1 (CST, #2352),
p-MEK1 (Epitomics, #1470), MEK2 (Epitomics, #1236), MOB1
(CST, #3863), p-MST1 (CST, #3681), MST1 (CST, #3682),
p-LATS1 (CST, #9157), LATS1 (CST, #3477) and GAPDH (CST,
#5174).Fig. 2. Inhibition of MEK reduces YAP expression and activities. (A) U0126 inhibits YAP
DMSO () or increasing concentration of U0126 (1–20 lM). (B) PD98059 inhibits YAP
increasing concentration of PD98059 (15–50 lM). (C) Inhibition of MEK reduces YAP acti
(15 lM U0126 or 30 lM PD98059) were co-transfected with a 5  UAS-Fireﬂy luciferase
were measured and normalized to cotransfected- Renilla luciferase. ⁄P < 0.05 and ⁄⁄P <
expression as measured by Western blotting. (E) U0126 and PD98059 do not affect YAP tr
HepG2 cells treated with either U0126 (15 lM) or PD98059 (30 lM). GAPDH mRNA wa2.3. Cell proliferation, soft-agar assays, and quantitative RT-PCR
Cell proliferation was measure by a MTT-based proliferation
assay [8], anchorage-independent soft-agar growth assay and
quantitative RT-PCR were performed as previously described [8].
2.4. Immunoprecipitation
Cell lysates were incubated with indicated antibodies and pro-
tein A/G beads (Iife technologies, Oslo, Norway) overnight. The
immunoprecipitates were washed ﬁve times, and then subjected
to Western blotting analysis.
2.5. Xenograft mouse model
5  106 Bel-7402 cells under different treatment as indicated
were subcutaneously injected into the athymic nude mice (Bikai,
Shanghai, China). Tumor size was measured every six days using
a caliper, and the tumor volume was calculated as 0.5  L W2,
with L indicating length and W indicating width. The mice were
euthanized at 24 days after injection.expression. Western blotting of YAP in Bel-7402 and SMMC-7721 cells treated with
expression. Western blotting of YAP in Bel-7402 cells treated with DMSO () or
vities. Bel-7402 and SMMC-7721 cells treated with DMSO (control) or MEK inhibitor
reporter (pUAS-LUC) and Gal4-TEAD expression vectors. Fireﬂy luciferase activities
0.01 using Student t test. (D) U0126 (15 lM) and PD98059 (30 lM) inhibit CTGF
anscription. YAP mRNA was evaluated by qPCR in control (DMSO) and Bel-7402 and
s used as loading control. Data was arbitrarily set to 100% for the control.
Fig. 3. No mutual effects between MEK/ERK and MST/Hippo pathways. (A) U0126
and PD98059 does not affect LATS/MST phorsphorylation as measured by Western
blotting for different proteins as indicated in Bel-7402 cells treated with DMSO ()
or increasing concentration of U0126 (1–20 lM, left panel) or PD98059 (15–50 lM,
right panel). (B) No mutual effects between MST and ERK. Western blotting of
related proteins involved in Hippo and MEK/ERK pathways in control (transfected
with Empty vector) and Bel-7402 cells with either MST1 (left panel) or ERK1 (right
panel) overexpressed.
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3.1. MEK and YAP play similar roles on tumorigenesis
As known, both MEK1 and MEK2 are important for cancers
[19,20], we tested their expression patterns in liver cancers and
their adjacent normal tissues. We found only MEK1 but not
MEK2 was up-regulated in liver cancers. Besides, the up-regulation
of p-MEK1 may due to the up-regulation of total MEK1, because
similar ratios between p-MEK1 and total-MEK1 were detected in
both cancer and normal tissues (Fig. 1A). Thereby, we mainly focus
on MEK1 in the following study. Next, we veriﬁed two MEK1 inhib-
itors, PD98059 and U0126 on their inhibitory effects on the phos-
phorylation of MEK1 (Fig. 1B) as well as its downstream target,
ERK1/2 (Fig. 1C). Furthermore, we found treatment of PD98059
and U0126 decreased cell proliferation compared to control
(Fig. 1D), and impaired the ability of these cells to form colonies
in soft agar (Fig. 1E). We then investigated the growth of Bel-
7402 clones after injection into athymic mice. Compared to the
control, both two MEK1 inhibitors effectively prevented tumor
growth (Fig. 1F). Furthermore, deletion of YAP by speciﬁc shRNA
had similar inhibitory effects on tumirogenesis as the two MEK1
inhibitors (Fig. 1D–F), suggesting a positive correlation between
YAP and MEK1.
3.2. Inhibitory to MEK1 reduces both YAP expression and activity
Next, we explored the close relationship between MEK1 and
YAP. We found that YAP could be reduced by both U0126
(Fig. 2A) and PD98059 (Fig. 2B) in a dose dependent manner. Fur-
thermore, when using a pUAS-Luc/TEAD-Gal4 reporter system as
established for testing YAP activity [4], we found YAP activities
were also signiﬁcantly reduced by both two MEK1 inhibitors as
compared to control (Fig. 2C). The decreased levels of CTGF, a wellknown YAP downstream target gene by treatment of MEK inhibi-
tors also conﬁrmed our hypothesis that MEK promotes YAP in liver
cancer cells (Fig. 2D). To role out the possibility that MEK affects
YAP at transcriptional levels, qPCR was performed and detected
no signiﬁcant alteration for YAP mRNA before and after treatment
of MEK inhibitors (Fig. 2E), thus suggesting the effect on YAP by
MEK may at post-transcriptional level.
3.3. MEK affects YAP independent of MST/LATS/Hippo as well as ERK
Because it was reported that regulation of YAP was controlled
by tumor suppressor Hippo pathway [21]. We tested if inhibitory
of MEK1 by the two inhibitors may stimulate Hippo pathway. Dis-
like inhibitory effects on YAP (Fig. 2A and B), phorsphorylation of
LATS1 and MTS1 even total-LATS1/MST1 and MOB1 remained un-
changed (Fig. 3A), indicating that down-regulation of YAP by MEK
inhibitors is Hippo pathway independent. Furthermore, activation
of Hippo pathway by overexpression of MST1 down-regulated YAP,
however; neither p-MEK1/MEK nor p-ERK1/2/ERK1/2 was affected
(Fig. 3B, left panel), suggesting YAP degradation by Hippo pathway
was independent of MEK/ERK as well. Also, when we transfected
with ERK1 expressing plasmids, YAP showed no signiﬁcant
changes (Fig. 3B, right panel), demonstrating that although ERK is
MEK’s direct downstream signaling effecter, it does not control YAP
protein expression.
3.4. MEK1 promotes YAP via their interaction
As described above, blockage of MEK1 reduced YAP expression
is neither dependent on ERK nor Hippo pathway, we postulated
that MEK1 may play a direct positive role to YAP. As chemical
inhibitors normally have side effects, we introduced two inde-
pendent MEK1 shRNAs, and found that in consistent with
PD98059 and U0126, knockdown of MEK1 reduced YAP expres-
sion (Fig. 4A). Because transaction of proteins relies on their
interaction, we then tested whether they interacts with each
other. We found that both MEK1 and YAP gave strong signals,
and co-localized in both HepG2 and Bel-7402 cells by IF assays
(Fig. 4B). Co-IP experiments also demonstrated that endogenous
YAP and MEK1 readily co-immunoprecipitated (Fig. 4C). Also,
exogenous MEK1-HA could be readily pulled down by YAP-Flag
(Fig. 4D). To further uncover the relationship between YAP and
MEK1, we performed IHC using TMA on 201 human liver cancer
samples. We found that both MEK1 and YAP proteins are highly
expressed in a subset of human liver cancers and closely corre-
lated with each other (Fig. 4E and F). Taken together, these exper-
iments establish a close relationship between MEK1 and YAP in
liver cancer.
3.5. MEK1 maintains YAP through BTRC
As previously reported, degradation of YAP is mediated by ubiq-
uitin E3-ligase BTRC after phorsphorylation by Hippo pathway
[21]. On the basis of this study, we hypothesized that inhibition
of MEK1 may facilitate up-regulation of BTRC. Surprisingly, BTRC
was dose dependently down-regulated by both PD98059 and
U0126 (Fig. 5A). Furthermore, BTRC could be reduced in cells with
MEK1 knocked down compared to the control (Fig. 5B), suggesting
MEK1 plays negative roles on BTRC. To further reveal the relation-
ship between endogenous BTRC and YAP, BTRC was knocked down.
We found that YAP was signiﬁcantly reduced, by contrast, p-MEK1/
MEK1 levels remained unchanged (Fig. 5C), indicating BTRC may
have another role that protects YAP from degradation. Further-
more, reduction of YAP by loss of MEK1 could be rescued when
BTRC was simultaneously overexpressed (Fig. 5D). The interaction
between BTRC and MEK1 was also conﬁrmed by both Co-IP (Fig. 5E
Fig. 4. Interaction between YAP and MEK1. (A) Knockdown of MEK1 reduces YAP expression. Western blotting of MEK1 and YAP in control (treated with GFP-shRNA) and Bel-
7402 or HepG2 cells with MEK1 knocked down. (B) Co-localization of YAP and MEK1. Cells were harvested for immunoﬂuorescence (IF) analysis by both anti-YAP and anti-
MEK1 antibodies. Scale bar, 15 lM. (C) Western blotting of co-immunoprecipitations (IP) of YAP and MEK1. The antibodies used in IP and Western blotting are shown as
indicated. Endogenous YAP immunoprecipitated endogenous MEK1 in lysates of HepG2 (left panel) and Bel-7402 cells (right panel). Non-speciﬁc IgG was used as a parallel
control. (D) YAP binds to MEK1. MEK1-HA was co-transfected with YAP-Flag into HEK293T cells as indicated. YAP and MEK1 associations were examined by co-IP as
indicated. (E and F) MEK1 correlates with YAP. Representative IHC images of MEK1 and YAP staining from the TMA analysis (E). Statistical analysis of the TMA data is shown in
the (F).
L. Li et al. / FEBS Letters 587 (2013) 3921–3927 3925and F) as well as IF assays (Fig. 5G), suggesting BTRC, MEK1 and
YAP may scaffold in the same complex.
3.6. Interaction between YAP and MEK1 promotes tumorigenesis
To investigate the roles of the interaction between YAP and
MEK1 on tumorigensis, MTT, colonies formation and xenograft
mice analysis were performed again. Compared to the control, cells
with MEK1 knocked down effectively prevented cell proliferation
(Fig. 6A), soft agar colonies formation (Fig. 6B) as well as tumor
growth in athymic mice (Fig. 6C), but such effects could be partly
rescued by simultaneously overexpressing YAP (Fig. 6A–C). Thus,
conﬁrmed the importance of this close relationship both in vitro
and in vivo.
4. Discussion
In this study,we foundMEK1maintainsYAPexpressionaswell as
function, as cellswith eitherMEK1 inactivatedorYAPknockeddown
exhibit similar effects that inhibit cell proliferationandmaintenance
of transformative phenotype (Fig. 1D–F). Furthermore, reduced
phosphorylation ofMEK1 by its inhibitors leads to signiﬁcant reduc-
tion of both YAP expression and activities (Fig. 2A–D), and such
effects are independent of transcription (Fig. 2E).
ERK is a pivotal downstream effecter of MEK, as RNAi-mediated
MEK knockdown prevents ERK activation and abolishes hepatocar-
cinoma growth [22]. However, in this study, we found MEK1regulates YAP via an ERK independent manner; because ectopic
expression of ERK has no effects on YAP (Fig. 3B). Moreover, the ef-
fect that MEK1 promotes YAP dose not rely on the inhibition of
Hippo pathway, as this tumor suppressor pathway can not be acti-
vated after blockage of MEK (Fig. 3A).
Through Co-IP and confocal microscopic analysis, we found
MEK1, BTRC and YAP may scaffold in the same complex
(Figs. 4B–D and 5E–G). MEK1 promotes YAP, or in other words,
protects YAP from degradation may partly depends through BTRC
(Fig. 5A–D), a well known F-box ubiquitin E3-ligase. However,
BTRC has been reported facilitates YAP degradation once Hippo
pathway is activated [21]. In our previous study, we also reported
that induction of BTRC by knockdown of tribbles homolog 2
(TRIB2) facilitates YAP degradation, suggesting BTRC is an impor-
tant regulator maintaining YAP expression in liver cancer [23]. Col-
lectively, we think BTRC may play dual roles on YAP: one role is
that when BTRC is overexpressed or Hippo pathway is activated,
it accelerates YAP turnover. On the other hand, loss of BTRC by
shRNA was unable to maintain YAP expression (Fig. 5C), thus when
at normal level, BTRC displays another role that protects YAP from
degradation. Since BTRC functions as a mediator of protein ubiqui-
tination and subsequent degradation [21,24], we suspect that BTRC
can exert differential effects through alternative ubiquitylation. As
Popov, et al. [25] reported that BTRC binds to Myc by means of a
characteristic phosphodegron and ubiquitylates Myc, which results
in enhanced Myc stability but not degradation. Through this mech-
anism, ubiquitination of YAP is BTRC dose dependent, at least in
Fig. 5. MEK promotes YAP by BTRC. (A) U0126 and PD98059 inhibits BTRC. Western blotting of BTRC in Bel-7402 (upper panel) and HepG2 cells (lower panel) treated with
DMSO () or increasing concentration of PD98059 (15–50 lM) or U0126 (1–20 lM). (B) Knockdown of MEK1 reduces BTRC as measured by Western blotting in control (GFP-
shRNA) and HepG2 cells with MEK1 knocked down. (C) BTRC affects YAP expression. Western blotting of proteins as indicated in control (GFP-shRNA) and Bel-7402 (left
panel) or HepG2 (right panel) with BTRC knocked down. (D) BTRC rescues knockdown of MEK1 induced YAP degradation. Western blotting of YAP in Bel-7402 cells under
different treatment as indicated. (E) Western blotting of co-immunoprecipitations (IP) of BTRC and MEK1. The antibodies used in IP and Western blotting are shown as
indicated. Endogenous BTRC immunoprecipitated endogenous MEK1 in lysates of Bel-7402 cells (upper panel) and HepG2 (lower panel). (F) MEK1-HA was co-transfected
with BTRC-Flag into HEK293T cells as indicated. MEK1 and BTRC associations were examined by co-IP as indicated. (G) Co-localization of BTRC and MEK1. Cells were
harvested for immunoﬂuorescence (IF) analysis by both anti-BTRC and anti-MEK1 antibodies. Scale bar, 15 lM.
Fig. 6. YAP rescues inhibitory effects by knockdown of MEK1. (A-B) Relative cell proliferation and transformation activities measured byMTT (A), and anchorage-independent
soft agar colony formation assays (B) in Bel-7402 and SMMC-7721 cells expressing shRNA constructs (sh#1+2) against MEK1 with or without ectopic expression of YAP. (C)
Ectopic expression of YAP rescues silencing of MEK1 (sh#1+2) in vivo. Tumor volumes were measured for 24 days after subcutaneous injection. n = 5 per group. ⁄P < 0.05 and
⁄⁄P < 0.01 using Student t test. (D) Possible mechanism underlying interaction between MEK1, BTRC and YAP.
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normal dose dependent stability. Another possibility is that BTRC
suppresses another YAP ubiquitylation related protein at normal
level, whereas enhances its effects at high dose level. Further
mechanism need to be explored.
In conclusion, we reported that YAP-MEK1 interaction is critical
for liver cancer cells both in vitro and in vivo (Fig. 6A–C). Moreover,
both MEK1 and YAP proteins are highly expressed in a subset of
human liver cancer samples and closely correlated (Fig. 4E and
F), suggesting an important role of this interaction in liver cancers
(Fig. 6D).Broke up of this interaction may serve as a crucial target
in liver cancer therapy.
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